Page 22 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is over 75% enrolled, with completion of enrollment expected in the coming weeks Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva

United kingdomAmber fennellBryan gibbsRedhill biopharmaAdi frishMarkl levittOpaganib yelivaUs department of defenseUs national institute of healthApogee biotechnology corpRedhill biopharma ltdExchange commissionCompany annual report on formCompany expanded access programCorporate business developmentOffice of orphan products development